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Inflammation is observed in Alzheimer’s disease (AD) subject brains. Inflammation-relevant
genes are increasingly implicated in AD genetic studies, and inflammatory cytokines to
some extent even function as peripheral biomarkers. What underlies AD inflammation is
unclear, but no “foreign” agent has been implicated.This suggests that internally produced
damage-associated molecular pattern (DAMPs) molecules may drive inflammation in AD. A
more complete characterization and understanding of AD-relevant DAMPs could advance
our understanding of AD and suggest novel therapeutic strategies. In this review, we con-
sider the possibility that mitochondria, intracellular organelles that resemble bacteria in
many ways, trigger and maintain chronic inflammation in AD subjects. Data supporting the
possible nexus between AD-associated bioenergetic dysfunction are discussed.
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INFLAMMATION IN AD
The role of inflammation in Alzheimer’s disease (AD) was first
observed approximately four decades ago (Ishii and Haga, 1976).
Beyond the identification of elevated immune cells and cytokines
in AD brain, many lines of evidence implicate inflammation as a
pathological AD hallmark. For instance, the use of non-steroidal
anti-inflammatory drugs (NSAIDs) associates with decreased AD
risk (Breitner et al., 1994; Rich et al., 1995). Additionally, a num-
ber of genes recently associated with AD risk through genome
wide association studies (GWAS) play a role in inflammation or
inflammatory signaling.
Abbreviations: ABCA7, ATP-binding cassette, sub-family A (ABC1), member 7;
AD, Alzheimer’s disease; AGE, advanced glycation endproduct; AKT, protein kinase
B; ATP, adenosine triphosphate; CCR3, C-C motif receptor 3; CCR5, C-C motif
receptor 5; CD33, cluster of differentiation 33; CLU, clusterin; CNS, central ner-
vous system; COX2, cyclooxygenase 2; COX-IV, cytochrome oxidase; CpG, cytosine
followed by guanine cite of methylation in DNA; CR1, complement receptor 1;
CRP, C reactive protein; CSF, cerebral spinal fluid; CXCR2, chemokine C-X-C
motif receptor 2; DAMP, damage-associated molecular pattern; DeMP, oxidant-
initiated degraded mitochondrial polynucleotides; ECAR, extracellular acidification
rate; EPHA1, epherin receptor A1; ERK, extracellular signal-regulated kinase; ETC,
electron transport chain; FDG-PET, fluorodeoxyglucose (18F) positron emission
tomography; fMLP, formyl-methionine, leucine, phenylalanine; FPR, formyl pep-
tide receptor; GPCR, G protein-coupled receptor; GWAS, genome wide association
study; HMGB1, high mobility group box 1; ICAM, intracellular adhesion molecule;
IFNα, interferon alpha; IL-1, interleukin 1; IL-6, interleukin 6; IL-8, interleukin 8; IL-
10, interleukin 10; IL-12, interleukin 12; INFγ, interferon gamma; iNOS, inducible
nitric oxide synthase; INPPD5, inositol polyphosphate-5-phosphatase; JNK, c-
Jun N-terminal kinase; LPS, lipopolysaccharide; MAC, membrane attack com-
plex; MAPK, mitogen activated protein kinase; MCI, mild cognitive impairment;
While an immediate response to an invasive pathogen is ben-
eficial, a sustained inflammatory reaction will lead to tissue dam-
age and functional decline. The cells responsible for an immune
response in the brain are microglia and astrocytes (Akiyama
et al., 2000a). In 1994, Akiyama et al. reviewed the contribu-
tion of microglial activation to neuroinflammation in AD. The
β-amyloid plaques of deceased AD patients were found to con-
tain significant amounts of activated microglia (Akiyama, 1994).
Microglia from AD patients express major histocompatibility
complex class II (MHCII) molecules, cyclooxygenase 2 (COX2),
and cytokines/chemokines such as monocyte chemotactic protein
MCP-1, monocyte chemotactic protein 1; MCP-3, monocyte chemotactic pro-
tein 3; MEFC2, myocyte-specific enhancer factor 2C; MHCII, major histocom-
patibility class II; MIP-1α, macrophage inflammatory protein 1 alpha; MIP-2α,
macrophage inflammatory protein 2 alpha; MMP-8, matrix metalloproteinase-8;
MPTP, methyl-4-phenyl-1,2,3,6-tetrahydropyridine; mtDNA, mitochondrial DNA;
NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP3,
NOD-like receptor family, pyrin domain containing 3; NO, nitric oxide; NSAID,
non-steroidal anti-inflammatory drug; OCR, oxygen consumption rate; PAI-1, plas-
minogen activator inhibitor-1; PAMP, pathogen-associate molecular pattern; PI3K,
phosphatidylinositol-4,5-bisphosphate 3-kinase; PRR, pattern recognition receptor;
PTK2B, protein tyrosine kinase 2 beta; RAGE, receptor for advanced glycation end-
products; RANTES, regulated on activation, normal T cell expressed and secreted;
RIG-1, retinoic acid inducible gene-1; RNS, reactive nitrogen species; ROS, reac-
tive oxygen species; SIRS, systemic inflammatory response syndrome; SNP, single
nucleotide polymorphism; TCA, citric acid cycle; TFAM, mitochondrial transcrip-
tion factor A; TGFβ, transforming growth factor beta; TLR, toll like receptor; TNBS,
2,4,6-trinitrobenzenesulfonic acid; TNFα, tumor necrosis factor alpha; tPA, tissue
plasminogen activator; TREM2, triggering receptor expresses on myeloid cells 2;
VCAM, vascular cell adhesion molecule.
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1 (MCP-1), TNFα, and IL-1β (Akiyama et al., 2000b). Postmortem
AD brain analysis depicted elevated IL-1α, CXCR2 (IL-8 receptor
β), CCR3 (C-C chemokine receptor type 3, CD193), CCR5 (C-
C chemokine receptor type 5, CD195), and transforming growth
factor β (TGFβ) (Cartier et al., 2005). The activity of numerous
immune system pathways are increased in AD, including comple-
ment, membrane attack complexes (MAC), and cytokines such
as; IL-1, IL-6, and TNFα. These have been extensively reviewed
elsewhere (Akiyama et al., 2000a).
Beyond direct measurement of inflammatory pathway media-
tors and effectors, brain inflammation can be measured in living
subjects through the use of PK11195. This molecule is an isoquino-
line carboxamide, which binds to the peripheral benzodiazepine
receptor. Within the context of the central nervous system (CNS),
PK11195 binds to glial cells, such as astrocytes and microglia.
Compared to control subjects, AD patients have elevated bind-
ing of radiolabeled PK11195. Furthermore, a correlation between
brain PK11195 labeling and cognitive deterioration is prominent
in AD patients (Cagnin et al., 2001; Versijpt et al., 2003).
Recent genetic association studies have revealed genes that reg-
ulate or encode inflammatory proteins associated with AD risk.
These are reviewed here and in Table 1. Two genes, which specif-
ically regulate phagocytosis influence AD risk. R47H, a novel
genetic variant of triggering receptor expressed on myeloid cells 2
(TREM2), impedes the normal function of this protein (Jonsson
et al., 2013). TREM2 functions to suppress cytokine production
and modulates microglial phenotype into a more phagocytic role.
Mutations of TREM2 reduce microglial phagocytosis by prevent-
ing its maturation and transport to the cell membrane (Klein-
berger et al., 2014). Cerebral spinal fluid (CSF) levels of soluble
TREM2 are reduced in AD subjects, although no significant differ-
ence is observed in plasma (Kleinberger et al., 2014). A potential
role for TREM2 in AD has been reviewed extensively elsewhere
(Jiang et al., 2013). The other gene, adenosine triphosphate (ATP)-
binding cassette subtype family A member 7 (ABCA7), encodes a
protein, which regulates macrophage phagocytosis and the trans-
port of molecules across the plasma membrane (Hollingworth
et al., 2011).
Single nucleotide polymorphisms of genes encoding compo-
nents of the complement cascade and MHC molecules enhance
AD risk. The complement system aids in antibody presentation
and phagocytosis processes relevant to the clearance of antigens or
inflammatory stimuli (Hazrati et al., 2012). Complement compo-
nent receptor 1 (CR1) and clusterin (CLU) associate with increased
AD risk (Lambert et al., 2009). CR1 is a type one transmem-
brane protein involved in activation of glial cells. CR1 activates
complement signaling and phagocytosis (Lambert et al., 2009).
CLU is a complement inhibitor, with other functions that relate
to apoptosis and modulation of NFκB signaling (Harold et al.,
2009; Lambert et al., 2009). MHC molecules present antigens
for immune responses, of which one single nucleotide polymor-
phisms (SNP) found in the HLA-DRB5/DRB1 gene is a risk
factor for AD.
Genes encoding proteins, which regulate immune cell func-
tion (EPHA1, INPPD5, and CD33) associate with AD risk. Ephrin
type A receptor 1 (EPHA1) is highly expressed in early stages
of inflammation and may play a role in the redistribution of
epithelial cell barriers (Ivanov and Romanovsky, 2006). EPHA1
also regulates cell motility and morphology. Phosphatidylinositol-
3,4,5-trisphosphate 5-phosphatase 1 (INPPD5) is expressed in
hematopoietic cells (which give rise to immune cells such as
macrophages and T cells). INPPD5 has been implicated in the
regulation of microglial cell function. CD33 is a transmembrane
receptor, which belongs to the Siglec family (sialic acid binding
immunoglobulin-type lectins, or carbohydrate binding proteins),
which bind and recognize sialic acid. Sialic acid is a general term
for derivatives of neuraminic acid or the keto-deoxynonulosonic
acid of nine-carbon sugars found on many proteins and lipids.
Sialic acids function to mediate selective cell-to-cell interactions
(Crocker and Varki, 2001). In particular, CD33 is expressed
Table 1 | Genetic variants associated with AD risk and inflammatory pathways.
Gene symbol Function Variation associated with AD Reference
TREM2 Phagocytosis/control of microglial phenotype rs75932628 (R47H) (Jiang et al., 2013; Jonsson et al., 2013;
Kleinberger et al., 2014)
CR1 Complement signaling phagocytosis rs6656401 (Lambert et al., 2009; Hazrati et al., 2012)
EPHA1 Epithelial cell barriers rs11767557 (Hollingworth et al., 2011)
Cell motility and morphology rs11771145
HLA-DRB5/DRB1 MHC signaling rs9271172 (Lambert et al., 2013)
INPPD5 Microglial cell function rs35349669 (Lambert et al., 2013)
MEFC2 Effector of MAPK signaling/activates c-Jun rs190982 (Lambert et al., 2013)
PTK2B Activates MAPK signaling rs28834970 (Lambert et al., 2013)
CD33 Cell–cell interactions rs3865444 (Hollingworth et al., 2011)
Immune cell function endocytosis rs3826656
ABCA7 Transporter rs3764650 (Hollingworth et al., 2011)
Phagocytosis rs3752246
CLU Complement NFκB signaling rs11136000 (Harold et al., 2009; Lambert et al., 2009)
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on myeloid cells where it promotes cell-to-cell interactions and
regulates inflammatory function (Hollingworth et al., 2011).
Single nucleotide polymorphisms which alter inflammatory
signaling pathways increase AD risk. Monocyte specific enhancing
factor 2 (MEFC2) is a transcription factor. Protein tyrosine kinase
2β (PTK2B), is a cytoplasmic tyrosine kinase. PTK2B activates p38
MAPK signaling, which ultimately activates inflammatory path-
ways, while MEFC2 is a downstream effector of p38 MAPK sig-
naling (Han et al., 1997). C-Jun activation is mediated by MEFC2,
and is thus highly associated with inflammatory cascades. Notably,
c-Jun is up-regulated in hippocampi from AD subject postmortem
brain tissue (Marcus et al., 1998). Genetic susceptibility loci and
polymorphisms for each of these genes have been associated with
AD risk (McGeer and McGeer, 2001; Ivanov and Romanovsky,
2006; Hollingworth et al., 2011; Hazrati et al., 2012; Lambert et al.,
2013).
To some extent peripheral inflammatory markers may reflect
one’s likelihood of developing dementia. Some conflict exists
regarding IL-6 and C reactive protein (CRP) correlation with
disease risk. While IL-6 and CRP levels positively correlate with
dementia risk, other studies found no association with AD risk
(Engelhart et al., 2004; Sundelof et al., 2009). A relationship
between IL-1, TNFα, and the development of AD has been
observed (Tan et al., 2007). In one eloquent longitudinal study,
midlife IL-6 elevation served as a predictor of cognitive decline
(Singh-Manoux et al., 2014). Thus, not only are plasma inflamma-
tory markers promising early biomarkers, inflammation-related
changes appear to precede the overt clinical dementia phenotype.
Strong evidence linking neuroinflammation and AD progres-
sion has propagated a new hypothesis termed “cycle of self-
perpetuating inflammatory neurotoxicity.” This hypothesis sug-
gests that after the initial inflammatory stimuli activates microglia,
the inflammatory tissue damage induces neuronal cell death that
ultimately propagates to other brain areas (Block et al., 2007).
Chronic inflammation is proposed to be a result of two possi-
ble factors; a lack of clearance of the inflammatory stimulus, or a
failure to resolve the inflammatory process (Glass et al., 2010). It
is further hypothesized that a disruption of homeostasis between
cell death and phagocytosis is a prominent factor contributing to
pathological inflammation in diseases (Zitvogel et al., 2010).
The factor or factors that initiate inflammation in AD remain
elusive. One factor that may substantially contribute to chronic
inflammation is bioenergetic dysfunction, which may arise at the
level of the mitochondria. We review the evidence for bioenergetic
dysfunction in AD below.
BIOENERGETIC DYSFUNCTION IN AD
The term “bioenergetics” refers to cell energy metabolism. Bioen-
ergetic flux is observed through the overall flow of individual
biochemical pathways (Swerdlow, 2014). Three major bioenergetic
pathways facilitate carbohydrate-based energy production – gly-
colysis, the Krebs cycle (or the citric acid cycle; TCA), and oxida-
tive phosphorylation. These pathways are commonly examined
when determining bioenergetic function. Glycolysis is an anaer-
obic process that takes place in the cytoplasm and results in low
energy yield. The aerobic TCA cycle and oxidative phosphory-
lation phases, which occur at the matrix and inner membrane of
mitochondria, respectively, can generate larger amounts of energy.
Bioenergetic flux is a multidirectional measurement, with forward
movement referring to the energy producing, catabolic direction
(i.e., glycolysis→TCA→ oxidative phosphorylation). The brain
is particularly vulnerable to reductions in aerobic bioenergetic flux
because of its high energy demand and relatively elevated mito-
chondrial content. Declining bioenergetic fluxes are observed in
aging and AD.
Extensive evidence correlates advancing age with declines in
overall bioenergetic function (Mecocci et al., 1994; Trifunovic
et al., 2004; Kujoth et al., 2005; Navarro and Boveris, 2007;
Boveris and Navarro, 2008; Swerdlow, 2011, 2012, 2014; Ross et al.,
2013). Decreased glucose utilization via fluorodeoxyglucose (18F)
positron emission tomography (FDG-PET) scan analysis is evident
in brains from aged individuals (De Santi et al., 1995; Chetelat et al.,
2013; Marano et al., 2013). Mitochondria play a prominent role
in contributing to the overall state of age-associated bioenergetic
decline. Aging mouse models show a continuous decrease in the
ability to produce ATP via oxidative phosphorylation at the mito-
chondrial membrane, and specifically a reduction in the Vmax
activities of Complexes I and IV of the electron transport chain
(ETC) (Navarro and Boveris, 2007, 2010). Minimal changes to
mitochondrial inner membrane permeability or F1-ATP-synthase
activity are observed in these aging mouse models. Furthermore,
the reduction in Complex I and IV Vmax activities correlates lin-
early with neurological performance and life span (Navarro and
Boveris, 2004, 2007; Boveris and Navarro, 2008). Several studies
of rats have shown that inhibiting cytochrome oxidase (COX-IV)
results in impaired long term potentiation, further demonstrat-
ing the importance of mitochondrial bioenergetic flux in memory
and learning (Parker et al., 1990; Bennett et al., 1992; Swerdlow and
Kish, 2002). Aging also results in increased reactive oxygen species
(ROS) production, a byproduct of dysfunctional mitochondria
and oxidative stress (Shigenaga et al., 1994; Ames et al., 1995).
Finally, accumulation of somatic mitochondrial DNA (mtDNA)
mutations has been implicated as an upstream component in aging
phenotypes (Doherty, 2003; Kujoth et al., 2005; Hiona et al., 2010).
Ample evidence indicates age-associated bioenergetic changes
are exacerbated in AD populations. Several decades of FDG-PET
analyses note a reduction in glucose utilization in AD subject
brains (Frackowiak et al., 1981; Foster et al., 1983; Friedland et al.,
1983). Analyses of mitochondria isolated from both brain and
platelets show an impaired bioenergetic capacity in AD patients.
More specifically, there are reductions in Complex I and IV
Vmax activity in AD subjects, along with minimal differences in
ATP-synthase activity (Mecocci et al., 1994; Maurer et al., 2000;
Bosetti et al., 2002). Postmortem examination of AD brain tis-
sue has revealed excessive oxidative stress and oxidative changes
to mtDNA (Mecocci et al., 1994; Manczak et al., 2004; Onyango
and Khan, 2006; Gibson et al., 2010). Pyruvate dehydrogenase and
α-ketoglutarate dehydrogenase are also impaired in AD subjects
(Parker et al., 1990; Kish, 1997; Gibson et al., 2010; Swerdlow,
2012).
Although parental history is an AD risk factor, individuals with
mothers afflicted with AD are more likely to develop AD than
individuals whose fathers have AD (Edland et al., 1996; Mosconi
et al., 2007; Honea et al., 2012). Children of mothers with AD have
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progressive reductions in brain glucose metabolism prior to any
overt cognitive defect (Mosconi et al., 2007). Children of cogni-
tively normal parents or fathers afflicted with AD, on the other
hand, do not show reductions in brain glucose utilization while
phenotypically healthy (Mosconi et al., 2007). As mtDNA is mater-
nally inherited, these data suggest mtDNA may influence AD risk
by in part determining an individual’s mitochondrial function and
bioenergetic capacity.
The cytoplasmic hybrid (cybrid) technique is a useful way to
observe the specific role of mtDNA within disease phenotypes.
The technique utilizes the mtDNA contained within donor platelet
samples and transfers it to cell lines depleted of endogenous
mtDNA. This approach results in the creation of cell lines with
an equivalent nuclear DNA background, but that vary in their
mtDNA content (Swerdlow, 2002; Wilkins et al., 2014). AD cybrid
lines, generated using neuroblastoma cell lines, have decreases in
COX activity, ATP, mitochondrial calcium concentration, mito-
chondrial membrane potential, and glycolytic flux (Sheehan et al.,
1997; Swerdlow et al., 1997; Ghosh et al., 1999; Silva et al., 2012,
2013). NFκB, MAPK, and AKT pathways are activated in AD
cybrids, while active caspase-3 and cytoplasmic cytochrome c are
elevated (Ghosh et al., 1999; Onyango et al., 2005; Silva et al., 2012,
2013; Wilkins et al., 2014). Finally, AD cybrids show increased
amyloid beta production and mimic the effects of oxidative stress
observed in aging and AD brains (Onyango et al., 2005). These
cybrid studies indicate the contribution of mtDNA to diminished
bioenergetic function and biochemical changes in AD.
It remains to be seen whether bioenergetic dysfunction rep-
resents an upstream or downstream pathology in AD. The
“mitochondrial cascade hypothesis,” proposed in 2004, asserts
that bioenergetic perturbations cause AD clinical and histologic
changes (Swerdlow and Khan, 2004). Bioenergetic dysfunction can
drive inflammation and, conversely, inflammation can also result
in bioenergetic dysfunction. Next, we will review the interplay
between these two AD-associated phenomena.
RELATIONSHIP BETWEEN INFLAMMATION AND
BIOENERGETIC DYSFUNCTION
Inflammation has the potential to initiate bioenergetic pertur-
bations. Microglia, the resident macrophages within the CNS,
function to sense possible pathogen-associated molecular patterns
(PAMPs) or damage-associated molecular patterns (DAMPs).
Upon activation, microglia produce increased amounts of the
reactive nitrogen species (RNS) nitric oxide (NO) due to an up-
regulation of inducible nitric oxide synthase (iNOS), and ROS
due to an increase in NADPH oxidase (Babior, 2004; Di Fil-
ippo et al., 2010). The main function of these free radicals is
to mitigate pathogens. However, surrounding cells are also sub-
ject to the effects of ROS and RNS. This damages DNA, lipids,
and proteins, and can affect overall mitochondrial function. In
one possible scheme, free radicals generated by microglia dur-
ing chronic inflammation states damage mtDNA, which disrupts
oxidative phosphorylation and further amplifies ROS/RNS pro-
duction in a cyclical process (Balaban et al., 2005; Fukui and
Moraes, 2008). This is exemplified by the finding that NO pro-
duction inhibits mitochondrial respiration. The effect is mediated
by direct competition of NO against oxygen binding to Complex
IV. In particular, astrocytes stimulated to produce NO showed
evidence of inhibited mitochondrial respiration (Brown, 1997).
Conversely bioenergetic dysfunction, particularly at the level
of the mitochondria, is known to induce inflammation. Inhi-
bition of Complex I with rotenone or methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) induces inflammatory changes both
in vitro and in vivo. Rotenone administration activates a human
microglial cell line and stimulates the production of ROS (Shaikh
and Nicholson, 2009). In a rat model, rotenone induces microglial
activation in the striatum and substantia nigra. Microglial acti-
vation occurs prior to dopaminergic neuron loss in this model
(Sherer et al., 2003). A separate study found that rotenone-
triggered dopaminergic neuron loss occurs through an NADPH
oxidase-dependent microglial response (Gao et al., 2003a).
Microglial activation is found in various models of MPTP neuro-
toxicity. NADPH oxidase, to some extent, is required for MPTP
neurotoxicity (Gao et al., 2003b; McGeer and McGeer, 2008;
Long-Smith et al., 2009).
Further models associate mitochondrial dysfunction with
inflammatory signaling. Inhibition of Complex I (rotenone) or
Complex III (antimycin A) in bone marrow-derived macrophages
induced IL-1β production, which was dependent on the nod-like
receptor family pyrid domain containing 3 (NLRP3) inflamma-
some (Zhou et al., 2011). In this same study, concomitant rotenone
administration with inhibition of mitophagy/autophagy pathways
caused an accumulation of damaged mitochondria and ROS pro-
duction with downstream IL-1β production (Zhou et al., 2011).
Macrophages lacking mtDNA (ρ0 cells) are not able to activate
caspase-1 in response to LPS and ATP (Nakahira et al., 2011).
This study indicates the requirement for functional mitochon-
drial respiration in the activation of caspase-1 and the NLRP3
inflammasome.
A further study utilized the cybrid model to generate cell
lines with mtDNA from different haplogroups. mtDNA hap-
logroups represent distinct population origins through defined
SNPs. This particular study compared the H haplogroup to the J
haplogroup. The J haplogroup had significantly decreased expres-
sion of seven mitochondrial-encoded ETC components (MT-
ND1, MT-ND2, MT-ND3, MT-ND4, MT-CO2, MT-CO3, and
MT-ATP6) (Cristina Kenney et al., 2014). Cybrids generated from
J haplogroup mtDNA donors had a reduced oxygen consump-
tion rate (OCR), a reduced OCR to extracellular acidification rate
(ECAR) ratio, and significantly reduced complement pathway and
other inflammatory gene mRNA levels (such as IL-33). This novel
study depicts the interplay between specific mtDNA sequences,
bioenergetic function, and inflammation.
It is increasingly apparent that bioenergetic function and
inflammation are interdependent processes. We further hypoth-
esize the release of DAMPs that derive from mitochondria may at
least, in part, drive inflammation in AD.
STERILE INFLAMMATION
Given the striking lack of evidence for pathogen-induced inflam-
mation in AD, it is reasonable to hypothesize a significant role for
non-pathogen initiated inflammation or sterile inflammation in
the disease pathology. DAMPs, also referred to as alarmins, are
endogenous molecules that are normally sequestered by the host
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FIGURE 1 | Damage-associated molecular pattern signaling
mechanisms. Mitochondrial components can induce a DAMP response
through the activation of TLR, FPR, RAGE, P2X7, and/or the NALP3
inflammasome. FPR is a GCPR. FPR signaling is mediated through PLC,
PIP2, IP3, and DAG. Downstream activation of PKC leads to signaling
through MAPK, PI3K, and activation of NFκB and NAPDH oxidase. TLR
receptors dimerize with Myd88 and can activate NFκB through RIP1
kinase, MAPK, or PI3K pathways. The TLR pathway also activates NADPH
oxidase. RAGE receptor signaling activates PKC and CdC42/Rac (or Ras).
Downstream PI3K, MAPK or JNK, and Erk1/2 are activated. This leads to
NFκB activation (in addition to SP1 and AP1). P2X7 activation leads to
NRLP3 inflammasome signaling. NLRP3 (or IL-1R) activation mediates
inflammasome signaling through NLRP3, ACS, and caspase-1 (or RIG-1).
Pro-IL-1 is cleaved into IL-1β and IL-1α. NFκB activation initiates transcription
of Pro-IL-1, IL-10, IL-18, IL-6, TNFα, along with many other cytokine and
chemotactic factors.
cell and are therefore recognized as danger signals. DAMPs are
released during the death and rupture of host cells. These mol-
ecules initiate inflammatory signaling cascades, thus leading to
sterile inflammation. DAMPs have been associated with traumatic
brain injury, ischemia-reperfusion, atherosclerosis, arthritis, and
systemic inflammatory response syndrome (SIRS) (Collins et al.,
2004; Pullerits et al., 2005; Porto et al., 2006; Foell et al., 2007;
Zhang et al., 2010; van Golen et al., 2013; Walko et al., 2014).
The inflammatory response stimulated by DAMPs is similar
to the response induced by PAMPs. Typically, these molecules
are recognized by a pattern recognition receptor (PRR), which
leads to the activation of transcription factors such as NFκB and
cytokine production. Despite this similarity, data suggest PRRs are
able to discriminate between PAMPs and DAMPs through CD24-
SiglacG/10 signaling (Kaczmarek et al., 2013). Figure 1 depicts the
pathways in which DAMP molecules can initiate inflammatory
signaling.
MITOCHONDRIAL COMPONENTS AS DAMPs
Mitochondria presumably arose through the modification of a
previously independent, respiratory competent prokaryotic cell.
This is supported by the fact that mitochondria share numerous
characteristics with bacteria. Several studies have examined the
ability of whole mitochondrial extracts to induce inflammation.
In particular, human plasmacytoid dendritic cells incubated with
total mitochondrial extracts up-regulate IFNα expression (Julian
et al., 2012). This requires the presence of mtDNA and toll-like
receptor 9 (TLR9)/receptor for advanced glycation endproducts
(RAGE) activation. Fractions from nuclear and cytoplasmic pools,
on the other hand,do not induce IFNα expression. A separate study
that treated human blood monocytes with total mitochondrial
extracts found increased IL-8 expression and secretion (Crouser
et al., 2009). Again, treatment with nuclear or cytoplasmic frac-
tions did not produce this result. In vivo and in vitro treatment
with disrupted mitochondria induced polymorphonuclear leuko-
cyte (PMN) migration and degranulation, calcium flux, MAPK
activation, and cytokine production that included increased lev-
els of matrix metalloproteinase-8 (MMP-8), IL-8, IL-6, and TNFα
(Zhang et al., 2010). Human neutrophils treated with ruptured
mitochondria showed increased calcium release, oxidative bursts,
and chemotaxis (Julian et al., 2013). Overall, it is not surprising
that a considerable number of molecules that derive from mito-
chondria act as DAMPs. These molecules are shown in Table 2 and
are reviewed below.
Mitochondrial DNA
Mitochondrial DNA shares many characteristics with bacterial
DNA. It is circular in structure, lacks histones, and contains
unmethylated CpG repeats and bound formyl-peptides. The mito-
chondrial genome encodes 11 components of the ETC and two
subunits of ATP synthase. The nuclear genome and mitochondrial
genome work in an organized and concerted manner to maintain
a functional ETC. mtDNA serves as a DAMP molecule in trauma
patients and in SIRS. In particular, the concentration of mtDNA
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Table 2 | Mitochondrial-derived DAMP molecules.
Mitochondrial derived-DAMP
molecule
Receptor
activated
Proteins activated/
up-regulated
Cytokines produced Reference
mtDNA TLR MAPK, MMP-8, NFκB IL-1β, IL-6, IL-8, MCP-1, TNFα (Oka et al., 2012; Zhang et al., 2014)
Cardiolipin NA ICAM, VCAM NA (Wan et al., 2014)
ATP P2X7, NLRP3 MMP9 CCL2, CCL7, CXCL2, IL-1β,
IL-6, IL-8, IL-10, IL-12, IL-18,
INFγ, TNFα
(Gourine et al., 2007; Piccini et al.,
2008; Riteau et al., 2010; Kurashima
et al., 2012; Cauwels et al., 2014)
fMLP FPR iNOS, NFκB, MAPK, PI3K IL-1β, IL-8 (Pan et al., 2000)
TFAM+/− mtDNA TLR, RAGE NFκB, PI3K IL-1β, IL-6, IL-8, TNFα (Julian et al., 2013; Little et al., 2014)
Cytochrome c NA NFκB IL-6,MCP-1, MIP-2, MIP-1α
RANTES, TNFα
(Pullerits et al., 2005)
HMGB1 TLR, RAGE ERK, ICAM, JNK, NFκB,
MAPK, SP1, VCAM
IL-8, MCP-1, PAI-1, tPA, TNFα (Scaffidi et al., 2002; Fiuza et al.,
2003; Mazarati et al., 2011)
NA, not available.
circulating in plasma predicts mortality in trauma patients (Zhang
et al., 2010; Nakahira et al., 2013).
Several studies have directly tested the ability of mtDNA to
induce inflammation. In a recent study, mouse primary astrocytes
were transfected with oxidant-initiated, degraded mitochondr-
ial polynucleotides (DeMPs) (Mathew et al., 2012). This lead
to the production of IL-6, MCP-1, TNFα, and IL-1β. DeMPs
can also be detected in human CSF samples. In human PMNs,
mtDNA induces MAPK activation and IL-8 production (Zhang
et al., 2010). mtDNA also induces inflammation in vivo. Intra-
articular injection of mtDNA in mice induces arthritis and TNFα
expression (Collins et al., 2004). The lungs of rats receiving intra-
venous injection of mtDNA exhibited up-regulation of TLR9,
NFκB, TNFα, IL-6, and IL-10 (Zhang et al., 2014). These results
were not recapitulated upon injection of nuclear DNA. A separate
study demonstrated mtDNA that eludes autophagy can induce
inflammation (Oka et al., 2012). Here, mice with cardiac-specific
deletion of DNAse II underwent pressure overload, which allowed
the release of mtDNA while subsequently inhibiting its degrada-
tion. Increased IL-1β and IL-6 were observed. Outcomes in these
mice were improved following the genetic ablation of TLR9. Over-
all, in various cell and tissue types mtDNA induces inflammatory
signaling and cytokine production through common mechanisms.
Mitochondrial transcription factor A
Mitochondrial transcription factor A (TFAM) binds to mtDNA
to initiate its transcription. Beyond its function in transcription
of mtDNA, TFAM can also be released from damaged and dying
cells, where it can act as a DAMP molecule. Specifically, treat-
ment of human peripheral blood monocytes, THP-1 monocytic
cells, or primary microglia from autopsy patients with TFAM and
IFNγ caused cell death in neuronal cell lines co-cultured with glial
cells. It was found that activation of the JNK pathway was nec-
essary for these results (Little et al., 2014). Stimulation of THP-1
monocytes with TFAM alone elevated expression of IL-1β, IL-
6, and IL-8, and this was enhanced by the addition of IFNγ.
An additional study found that TFAM alone or in combination
with formyl-peptides induced IL-8 release from human blood
monocytes in a formyl peptide receptor (FPR)-dependent manner
(Crouser et al., 2009).
The combination of TFAM bound to mtDNA can also induce
inflammation (Julian et al., 2012, 2013). This was demonstrated
in human plasmacytoid dendritic cells, which up-regulated IFNα
expression and release upon exposure to TFAM-bound mtDNA.
In this study, inhibition of RAGE and TLR9 inhibited IFNα
expression. PI3K, ERK, and NFκB signaling were also implicated.
Mouse splenocytes treated with a combination of TFAM and
CpG-enriched mtDNA released TNFα in a TLR9 and RAGE-
dependent manner (Julian et al., 2013). PI3K and NFκB were also
required for TNFα expression. Thus, TFAM can induce inflam-
mation either alone or in combination with other mitochondrial
components.
Cardiolipin
Mitochondrial lipids also have prokaryotic features. Cardiolipin
is a unique lipid found in bacteria and the mitochondrial inner
membrane. Cardiolipin is essential to mitochondrial function.
Cardiolipin also acts as a mitochondrial-derived DAMP mole-
cule. Anti-cardiolipin antibodies are found in some autoimmune
diseases, including lupus (Ishii et al., 1990). Further, treatment of
human monocyte-derived macrophages with oxidized cardiolipin
induced the expression of intracellular adhesion molecule (ICAM-
1, also known as CD54) and vascular cell adhesion molecule
(VCAM-1, also known as CD106) (Wan et al., 2014). Non-oxidized
cardiolipin failed to elicit similar responses. While cardiolipin has
the potential to induce inflammation and act as a DAMP molecule,
at this time there is little direct evidence to suggest it commonly
functions in this capacity.
Cytochrome c
Cytochrome c is a small protein that is tethered by cardiolipin
to the inner mitochondrial membrane. It serves as an electron
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donor and acceptor during oxidative phosphorylation. The release
of cytochrome c from mitochondria induces apoptosis, while its
extracellular release initiates a DAMP response. Intra-articular
injection of cytochrome c in mice induces arthritis (Pullerits
et al., 2005). In addition, exposing mouse splenocytes to exogenous
cytochrome c activates NFκB as well as TNFα, IL-6, macrophage
inflammatory proteins (MIP-2α or CXCL2; MIP-1α or CCL3),
MCP-1, and RANTES (regulated on activation, normal T cell
expressed) production. Circulating cytochrome c can be mea-
sured in patients with liver injury, SIRS, and myocardial infarction
(Krysko et al., 2011). Similar to cardiolipin, antibodies against
cytochrome c are found in lupus patients (Mamula et al., 1990).
Adenosine triphosphate
The main function of mitochondria in many cell types is to pro-
duce ATP through oxidative phosphorylation. A release of ATP
occurs during cell death through either an active mechanism
prior to loss of cell membrane integrity, or via a passive process
after cell membranes become permeable (Zitvogel et al., 2010).
ATP facilitates the recruitment of macrophages and activation of
the NLRP3 inflammasome through P2X7 purinergic receptors.
In a mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)
induced-colitis, genetic knockout of P2X7 in mast cells reduced
intestinal inflammation and IL-6, TNFα, MCP-1, MCP-3, and
MIP-2α cytokine production (Kurashima et al., 2012). Inhibition
of ADP-responsive P2Y receptors (P2Y1 and P2Y12) had no effect
on inflammation observed in this model.
Using LPS-induced shock in mice, a separate study demon-
strated a requirement for extracellular ATP in inflammation
(Cauwels et al., 2014). This study used an ATP degrading enzyme,
apyrase, to show extracellular release of ATP is required for inflam-
mation and IL-1β, TNFα, and IL-10 cytokine production. In this
study, genetic ablation of P2X7 receptors also mitigated cytokine
production (Riteau et al., 2010). Conversely, when ATP-γS (a stable
ATP derivate) was administered, inflammation was enhanced.
Within the CNS, extracellular ATP can serve as a DAMP mol-
ecule and also plays a role in the regulation of body temperature,
cardiovascular function, and respiratory control (Gourine et al.,
2007). As a DAMP molecule, ATP initiates TNFα release from
cultured rat microglia in a calcium-dependent manner (Hide
et al., 2000). Extracellular ATP treatment of microglia enhanced
expression of MAPK and ERK, and inhibition of these pathways
prevented production of TNFα. Primary rat cortical astrocytes
treated with LPS release TNFα, while ATP treatment alone has no
effect (Kucher and Neary, 2005).
In vivo injection of LPS into rat striatum activates P2X7 recep-
tors (Choi et al., 2007). Blocking these receptors inhibits MAPK
and NFκB activation, and inhibits the production of COX2, IL-1β,
IL-6, IL-12, and TNFα. Other studies have shown a differential
effect of ATP on inflammation. ATP-induced TNFα release in
microglia cells was found to protect co-cultured neurons exposed
to glutamate (Suzuki et al., 2004).
In one study, injection of LPS into the anterior hypothalamus of
rabbits induced an extracellular ATP release (Gourine et al., 2007).
The concentration and timing of this extracellular ATP release
appeared to associate with a thermoregulatory febrile response
(Gourine et al., 2007).
Formyl-peptides
Formyl-peptides are found in both mitochondrial compart-
ments and bacteria. In particular, formyl-methionine–leucine–
phenylalanine (fMLP) is known to act as a DAMP molecule. In
human peripheral blood monocytes, fMLP induces NFκB acti-
vation and IL-1β production in a PI3K-dependent manner (Pan
et al., 2000). Similar results were observed in murine peritoneal
macrophages. fMLP stimulation led to activation of NFκB, PI3K,
and MAPK pathways. Furthermore, iNOS expression and NO pro-
duction were increased, an effect that depended on L-arginine
(Sodhi and Biswas, 2002).
In PMN cells, fMLP results in calcium release and chemotaxis
(Raoof et al., 2010). fMLP also induces inflammation in microglial
cultures. Mixed cultures of neurons and glia stimulated with
fMLP showed selective dopaminergic neuron loss and decreased
dopamine uptake (Gao et al., 2008). Pharmacologic inhibition
or genetic ablation of NADPH oxidase blocked fMLP toxicity.
fMLP-related microglial activation was associated with changes
in morphology, MHC II expression, and extracellular superoxide
production. Formyl-peptides, specifically those with the sequence
fMLP, therefore, initiate inflammation in peripheral and CNS cell
models.
High mobility group box 1
High mobility group box 1 is normally considered a nuclear pro-
tein, however, under both normal and pathological conditions it
localizes to mitochondria (Stumbo et al., 2008; Tang et al., 2010).
The oxidation state of high mobility group box 1 (HMGB1) may
influence its cellular localization (Tang et al., 2010). In the nucleus,
HMGB1 functions to regulate transcription through interac-
tions with histones and transcription factors. It also functions
as a cytokine. In mitochondria, HMGB1 regulates mitochon-
drial “quality control” (Tang et al., 2010). Immune cells (such
as macrophages) actively secrete HMGB1 during inflammation
(Andersson and Tracey, 2011). Recent studies have also depicted
the DAMP function of HMGB1. In mice, intracerebroventricular
injection of HMGB1 caused memory deficits through TLR4 and
RAGE-dependent pathways (Mazarati et al., 2011).
High mobility group box 1 also mediates inflammation in vitro.
Necrotic mouse fibroblast cells release HMGB1, stimulating
inflammatory changes such as increased TNFα production via
NFkB (Scaffidi et al., 2002). Indeed,necrotic fibroblast cells derived
from HMGB1 null mice are not capable of inducing inflammation.
Exogenous incubation of human microvascular endothelium cells
with HMGB1 induces expression of ICAM-1, VCAM-1, RAGE,
TNFα, IL-8, MCP-1, plasminogen activator inhibitor-1 (PAI-1),
and tissue plasminogen activator (tPA) (Fiuza et al., 2003). Cell
signaling pathways and transcription factors that are activated
include MAPK, ERK, JNK, NFκB, and SP1.
MECHANISMS FOR MITOCHONDRIAL-DERIVED DAMP RELEASE
Specific mitochondrial components clearly act as DAMP mole-
cules. Beyond this, total mitochondrial extracts induce inflamma-
tion in several cell types (Crouser et al., 2009; Zhang et al., 2010;
Julian et al., 2012, 2013). There is mounting evidence in the litera-
ture supporting mechanisms in which mitochondrial components
(either as part of whole mitochondria or as specific molecules)
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can be released from cells. For example, mitochondria that escape
autophagy (specifically, mitophagy) have the potential to stimu-
late an inflammatory response (Oka et al., 2012). A recent study
showed that retinal ganglion cells shed mitochondria at the optic
nerve head (Davis et al., 2014). Mitochondria shed by these neu-
rons are then internalized by surrounding astrocytes and degraded.
The authors of the study referred to this process as transmitophagy,
or transcellular degradation of mitochondria. This process is also
suspected to occur in other parts of the CNS, as similar accumula-
tions of degrading mitochondria are found in superficial layers of
the cerebral cortex alongside neurites. Finally, extracellular release
of mitochondrial components could be a consequence of cell death
pathways, such as necrosis or, possibly necroptosis (Kaczmarek
et al., 2013).
EVIDENCE FOR MITOCHONDRIAL-DERIVED DAMPs IN AD PATHOLOGY
As discussed above, several mitochondrial components can act
as DAMP molecules and evoke inflammatory signaling cas-
cades. Here, we discuss relevant data, which suggest a role for
mitochondrial DAMPs in AD pathology.
DAMP signaling in AD
Inflammasomes, particularly NLRP3 (or NALP3), have recently
generated interest in the AD research field (Shaftel et al., 2008).
Several components comprise the NLRP3 inflammasome includ-
ing NLR protein, ASC adaptor protein, and pro-caspase-1.
Retinoic acid inducible gene-1 (RIG-1) is another potential com-
ponent of the inflammasome. Upon activation, the NLR protein
activates transcription of pro-IL-1β and the formation of the
NLRP3 inflammasome complex. After this, the NLRP3 inflamma-
some cleaves and activates pro-IL-1β and downstream molecules
can be activated. Inflammasome signaling has been extensively
reviewed elsewhere (Latz et al., 2013). Current data suggest IL-1β
polymorphisms may associate with AD risk, although caspase-1
polymorphisms do not (Griffin et al., 2000; McGeer and McGeer,
2001; Shaftel et al., 2008; Vazquez-Higuera et al., 2010).
IL-1β levels are increased in CSF and serum from AD patients
(Cacabelos et al., 1991; Blum-Degen et al., 1995; Licastro et al.,
2000). Furthermore, IL-1 is found in microglia surrounding
plaques in postmortem AD brain tissue (Griffin et al., 1989). IL-1β
experimentally induces the disruption of the BBB and leukocyte
recruitment to the CNS while also blocking LTP in the hippocam-
pus (Shaftel et al., 2008). Elevated expression of active caspase-1
has also been detected in AD brain tissue (Heneka et al., 2013).
RIG-1, a component of inflammasome signaling, is elevated in
plasma and temporal cortex in mild cognitive impairment (MCI,
frequently a precursor syndrome of AD) subjects (de Rivero Vac-
cari et al., 2014) Therefore, many lines of evidence suggest the
NLRP3 inflammasome is relevant to AD.
Toll like receptors may also play a pivotal role in AD. Spe-
cific TLR9 polymorphisms have been associated with a decreased
AD risk, while specific TLR4 polymorphisms have been associ-
ated with an increased risk (Balistreri et al., 2008; Wang et al.,
2011, 2013). There is some conflict in the literature regarding
the association of TLR2 genetic polymorphisms in AD (Yu et al.,
2011a,b). In blood (PBMCs specifically) and brain tissue from AD
patients, TLR2 and TLR4 are increased (Liu et al., 2005; Walter
et al., 2007; Letiembre et al., 2009; Zhang et al., 2012). TLR activa-
tion leads to receptor dimerization at the plasma membrane with
the adaptor protein MyD88, activation of the RIP1 kinase, and
downstream signaling to NFκB and MAPK. Changes in levels of
IL-6, IL-8, IL-12, and TNFα have been reported. Similar changes
are observed in AD (Singh and Guthikonda,1997; Swardfager et al.,
2010; Cojocaru et al., 2011; Alsadany et al., 2013). While a lack of
data exists regarding MyD88 in human AD patients, in one AD
mouse model genetic ablation of MyD88 was found to mitigate
microglial activation and amyloid beta toxicity (Lim et al., 2011).
Formyl peptide receptors are seven transmembrane domain-
configured G protein-coupled receptors (GPCRs). Activation of
FPRs can induce cell adhesion, chemotaxis, ROS release, pro-
duction of pro-inflammatory cytokines, and phagocytosis. Upon
stimulation, FPRs bind G proteins and execute the activation of
signaling pathways including, PI3K, IPR3 (which mediates ER
calcium efflux), and NFκB. This leads to downstream NADPH oxi-
dase respiratory flux and cytokine production. FPRs have attracted
interest in AD due to the binding capacity of the amyloid beta pep-
tide (Verdier et al., 2004). While the downstream effectors of FPR
signaling are implicated in AD histopathology, no direct evidence
of activation of FPRs in AD patients has currently been published.
RAGE was initially identified in lung tissue, where it was
found to bind advanced glycation endproducts (AGEs) (Xie et al.,
2013). Numerous cell processes are activated through RAGE sig-
naling including cell motility, proliferation, autophagy, inflam-
mation, and apoptosis. Inflammatory signaling cascades activated
downstream of RAGE include MAPK, JNK, and NFκB. Produc-
tion of pro-inflammatory cytokines, including IL-6, IL-8, TNFα,
and COX2, are mediated through these signaling cascades. Sev-
eral mitochondrial-derived DAMPs can induce RAGE activation,
including the combination of TFAM and CpG mtDNA (Julian
et al., 2013). RAGE also binds amyloid beta, a finding that suggests
a possible association between RAGE and AD (Verdier et al., 2004;
Xie et al., 2013). Microglia from AD subjects show increased RAGE
expression (Lue et al., 2001).
Mitochondrial-derived DAMPs in AD
Few mitochondrial-derived DAMP molecules have been measured
in actual AD patients. CSF concentrations of cell-free circulat-
ing mtDNA are reduced in AD patients (Podlesniy et al., 2013).
This finding is of interest because while amyloid beta levels are
high in AD brain and plasma, CSF levels of amyloid beta are
decreased (Mehta et al., 2000; Wallin et al., 2006; Buchhave et al.,
2012). How CSF concentrations of molecules (such as proteins
and DNA) relate to their respective brain concentrations at this
time, therefore, is incompletely understood. Another study that
reported DeMPs induce inflammation in primary mouse astro-
cytes (Mathew et al., 2012) also reported the detection of DeMPs
in human CSF and plasma samples. However, no current data are
available to show whether DeMP levels in AD subjects exceeds
levels in non-demented control subjects.
Cerebral spinal fluid cytochrome c levels are increased in MCI
patients, and to some extent can predict conversion to AD. More
specifically, cytochrome c levels are increased in MCI subjects who
ultimately convert to the AD clinical phenotype (Papaliagkas et al.,
2009).
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CONCLUSION
Inflammation and bioenergetic dysfunction are important patho-
logical phenomena in AD. Inflammation and bioenergetic dys-
function can exhibit a cyclical relationship. Given the relation-
ship between these two pathologies and their interdependence on
mitochondria we hypothesize that DAMPs derived from mito-
chondria contribute to the initiation of inflammation in AD.
The release of mitochondrial components could occur through
necrotic cell death, transcellular mitophagy, or other currently
undefined mechanisms. The presence of inflammation may, in
turn, further perturb brain bioenergetic function. Basic evidence
for a DAMP response in AD is currently supported by existing
literature, although further investigation is needed to specifically
define the contribution of mitochondrial DAMPs to chronic brain
inflammation in this disease.
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